Solid Biosciences COO awarded 79,341 RSUs
Howton David T reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Howton David T reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. reported that Chief Operating Officer David T. Howton received a grant of 79,341 restricted stock units (RSUs), each representing a contingent right to one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, where 25% of the target RSUs vest upon each of four predetermined performance milestones.
The Board determined that the second performance milestone was met on January 29, 2026, triggering this portion of the award. The shares tied to this milestone are scheduled to vest in the first quarter of 2027, subject to Mr. Howton’s continued service with the company on the evaluation date. This is a compensation-related equity award, not an open-market stock purchase.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 79,341 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
- F2. Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Key Figures
Key Terms
Restricted Stock Units financial
Performance stock units financial
Performance Milestones financial
non-market and non-financial in nature financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Solid Biosciences (SLDB) report for David T. Howton?
How many RSUs did the Solid Biosciences COO receive in this Form 4 filing?
What are the key terms of the performance stock units disclosed by Solid Biosciences (SLDB)?
When will the 79,341 RSUs reported for Solid Biosciences’ COO vest?
What performance milestone triggered the RSU grant to Solid Biosciences’ COO?
AI-generated analysis. How Rhea-AI works. Not financial advice.